Analysts' ratings for Stericycle SRCL over the last quarter vary from bullish to bearish, as provided by 6 analysts.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 2 | 2 | 1 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 2 | 1 | 1 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $62.17, a high estimate of $75.00, and a low estimate of $48.00. Marking an increase of 11.02%, the current average surpasses the previous average price target of $56.00.
Understanding Analyst Ratings: A Comprehensive Breakdown
The perception of Stericycle by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| David Manthey | Baird | Lowers | Neutral | $55.00 | $62.00 |
| Sean Dodge | RBC Capital | Maintains | Outperform | $69.00 | - |
| John Mazzoni | Wells Fargo | Raises | Underweight | $48.00 | $40.00 |
| Sean Dodge | RBC Capital | Raises | Outperform | $69.00 | $58.00 |
| Michael Hoffman | Stifel | Raises | Buy | $75.00 | $70.00 |
| Tobey Sommer | Truist Securities | Raises | Hold | $57.00 | $50.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Stericycle. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Stericycle compared to the broader market.
- Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Stericycle's stock. This examination reveals shifts in analysts' expectations over time.
Capture valuable insights into Stericycle's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Stericycle analyst ratings.
Unveiling the Story Behind Stericycle
Stericycle is the largest provider of medical waste disposal and data destruction (primarily paper shredding) services in the United States. Its next-closest national competitor in medical waste disposal is Sharps Compliance, which generated $76 million of sales in fiscal 2021 before its 2022 acquisition (about 4% of Stericycle's global regulated waste and compliance revenue). Stericycle's data destruction business, Shred-It, is about twice the size of its closest competitor (Iron Mountain's information destruction segment). Stericycle has a global presence, with about 20% of its revenue earned outside North America.
Stericycle: Delving into Financials
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Decline in Revenue: Over the 3 months period, Stericycle faced challenges, resulting in a decline of approximately -2.73% in revenue growth as of 31 December, 2023. This signifies a reduction in the company's top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Stericycle's net margin is impressive, surpassing industry averages. With a net margin of 2.29%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Stericycle's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 0.6%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Stericycle's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.28%, the company showcases efficient use of assets and strong financial health.
Debt Management: Stericycle's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.71.
Analyst Ratings: Simplified
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
